Effect of an activated charcoal product (DOAC Stop™) intended for extracting DOACs on various other APTT-prolonging anticoagulants

@article{Exner2019EffectOA,
  title={Effect of an activated charcoal product (DOAC Stop™) intended for extracting DOACs on various other APTT-prolonging anticoagulants},
  author={T. Exner and M. Ahuja and Lisa Ellwood},
  journal={Clinical Chemistry and Laboratory Medicine (CCLM)},
  year={2019},
  volume={57},
  pages={690 - 696}
}
  • T. Exner, M. Ahuja, Lisa Ellwood
  • Published 2019
  • Medicine
  • Clinical Chemistry and Laboratory Medicine (CCLM)
    • Abstract Background The aim of the study was to investigate the specificity of an activated charcoal-based product (DOAC Stop™) initially intended for the specific extraction of direct oral anticoagulants (DOACs) from test plasmas on a range of other anticoagulants. Methods Test plasmas were prepared by adding various anticoagulants to pooled normal plasma at concentrations prolonging an activated partial thromboplastin time (APTT) test by a factor of 1.5–3. These plasmas were treated with DOAC… CONTINUE READING
    View on Wolters Kluwer
    ncbi.nlm.nih.gov
    12 Citations
    Background Citations
    2
    Methods Citations
    1
    Results Citations
    1
    12 Citations
    Citation Type

    Citation Type

    The effect of DOACs on laboratory tests and their removal by activated carbon to limit interference in functional assays
    • 2
    A diagnostic solution for haemostasis laboratories for patients taking direct oral anticoagulants using DOAC‐Remove
    • 11
    Clotting test results correlate better with DOAC concentrations when expressed as a "Correction Ratio"; results before/after extraction with the DOAC Stop reagent.
    • 5
    Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban
    • L. Slavík, J. Jáčová, +5 authors M. Palová
    • Medicine
    • Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    • 2019
    • 9
    Antiphospholipid Syndrome Committee of the Brazilian Society of Rheumatology position statement on the use of direct oral anticoagulants (DOACs) in antiphospholipid syndrome (APS)
    Neutralising rivaroxaban induced interference in laboratory testing for lupus anticoagulant (LA): A comparative study using DOAC Stop and andexanet alfa.
    • 20
    • PDF
    Direct oral anticoagulant adsorption: Impact on lupus anticoagulant testing—Review of the literature and evaluation on spiked and patient samples
    The effect of unfractionated heparin, enoxaparin, and danaparoid on lupus anticoagulant testing: Can activated carbon eliminate false‐positive results?
    • 8
    Consultative Interpretation for Lupus Anticoagulant by Expert Pathologist Reduces False-Positive Rates in the Era of Direct Oral Anticoagulants.
    • PDF
    Anti‐factor IIa (FIIa) heparin assay for patients on direct factor Xa (FXa) inhibitors

    References

    SHOWING 1-10 OF 17 REFERENCES
    Simple method for removing DOACs from plasma samples.
    • 44
    The prolonged activated clotting time (ACT) with aprotinin depends on the type of activator used for measurement
    • 54
    Evaluation of the DOAC-Stop® Procedure to Overcome the Effect of DOACs on Several Thrombophilia Screening Tests
    • 32
    • PDF
    Antidotes for novel oral anticoagulants: current status and future potential.
    • 104
    Effect of Activated Charcoal on Apixaban Pharmacokinetics in Healthy Subjects
    • 115
    • PDF
    Effect of Activated Charcoal on Rivaroxaban Complex Absorption
    • 15
    The adsorption of dabigatran is as efficient as addition of idarucizumab to neutralize the drug in routine coagulation assays
    • 17
    The effects of protamine overdose on coagulation parameters as measured by the thrombelastograph
    • 49
    • PDF
    Inhibition of Hageman factor activation.
    • 76
    • PDF
    Diagnostic methodologies for circulating anticoagulants.
    • T. Exner
    • Medicine
    • Thrombosis and haemostasis
    • 1995
    • 35